Literature DB >> 3548341

Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.

Y W Cheung, J C Cradock, B R Vishnuvajjala, K P Flora.   

Abstract

The stability of cisplatin, iproplatin, carboplatin, and tetraplatin in common intravenous solutions was studied. Admixtures of each drug in each of the following vehicles were prepared in glass containers: 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, 5% dextrose and 0.45% sodium chloride injection (admixtures were prepared in plastic bags also), and 5% dextrose and 0.225% sodium chloride injection. Drug concentrations were monitored for 24 hours using stability-indicating high-performance liquid chromatographic methods. The stability of cisplatin and tetraplatin was related to the chloride ion content of the infusion fluid; when the infusion fluid contained 0.9% sodium chloride, each of these drugs was present at greater than 90% of the original concentration after six hours. The stability of iproplatin was not related to chloride concentration. A slight increase in the decomposition rate of carboplatin was observed in the presence of chloride ion. Carboplatin and iproplatin are stable for 24 hours in all the infusion fluids studied, but carboplatin should not be diluted with solutions containing chloride ions because of possible conversion to cisplatin. Cisplatin is stable for 24 hours in admixtures containing sodium chloride concentrations of 0.3% or greater. Tetraplatin is stable for six hours in admixtures containing sodium chloride concentrations of at least 0.018%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3548341

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  13 in total

1.  Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

Authors:  Jamie Nguyen; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2016-06

2.  Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.

Authors:  Julie M Akin; J Aubrey Waddell; Dominic A Solimando
Journal:  Hosp Pharm       Date:  2014-05

Review 3.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container's material.

Authors:  M Pujol Cubells; J Prat Aixela; V Girona Brumos; S Duran Pou; M Villaronga Flaque
Journal:  Pharm World Sci       Date:  1993-02-19

Review 5.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

6.  Paclitaxel, Carboplatin, and trastuzumab.

Authors:  Jennifer Lee; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2014-11

Review 7.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

8.  Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

Authors:  H J Guchelaar; D R Uges; P Aulenbacher; E G de Vries; N H Mulder
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

Review 9.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 10.  A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions.

Authors:  D A Williams; J Lokich
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.